Case 24-80040-sgj11 Claim 4-1 Filed (17/22/24 Desc Main Document Page 1 of 13 Claim #56 Date Filed: 7/22/2024

Your claim can be filed electronically on Verita's website at https://epoc.veritaglobal.net/Eiger

United States Bankruptcy Court for the Northern District of Texas									
Indicate Debtor against which you asse	ert a claim by checking the appropriate box below. (Check only	one Debtor per claim form.)							
,	, , , , , , , , , , , , , , , , , , , ,	,							
X Eiger BioPharmaceuticals, Inc. (Case No. 24-80040)	☐ EB Pharma LLC (Case No. 24-80042)	☐ EigerBio Europe Limited (Case No. 24-80044)							
, ,	,	9 (()							
☐ EBPI Merger Inc. (Case No. 24-80041)	☐ Eiger BioPharmaceuticals Europe Limited (Case No. 24-80043)								
= 25. ·o.gore. (Gues rie. 2 / Goo ·)									

Modified Official Form 410

Proof of Claim 04/22

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Other than a claim under 11 U.S.C. § 503(b)(9), this form should not be used to make a claim for an administrative expense arising after the commencement of the case.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies or any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. Do not send original documents; they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed.

P	identity the Clair	m				
1.	Who is the current creditor?	Fujifilm Diosynth Biotechnologies, U.S.A, Inc. Name of the current creditor (the person or entity to be paid for this class). Other names the creditor used with the debtor	laim)	<u> </u>		
2.	Has this claim been acquired from someone else?	☐ Yes. From whom?				
3.	Where should notices and payments to the creditor be sent?	where should notices to the creditor be sent? c/o Michael L. Schuster, Polsinelli PC Name 1401 Lawrence Street, Suite 2300	Where should payments to the creditor be sent? (if different)			
	Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)	Number Street Denver, CO 80231 City State ZIP Code	Number Street City State ZIP Code			
		Contact phone Contact email T20-931-1188 Contact email Tachuster@polsinelli.com Uniform claim identifier for electronic payments in chapter 13 (if you us	Country Contact phone Contact email use one):			
4.	Does this claim amend one already filed?	No Yes. Claim number on court claims registry (if known)	n) Filed on	_		
5.	Do you know if anyone else has filed a proof of claim for this claim?	No Yes. Who made the earlier filing?				

Case 24-80040-sgj11 Claim 4-1 Filed 07/22/24 Desc Main Document Page 2 of 13

P	art 2: Give Information Ab	out the Claim as of the Date the Case Was Filed							
6.	Do you have any number you use to identify the	X No							
	debtor?	Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor:							
7.	How much is the claim?	S 202,280.00 Does this amount include interest or other charges? No X Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).							
8.	What is the basis of the claim?	Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card. Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c). Limit disclosing information that is entitled to privacy, such as health care information. Master Bioprocessing Services Agreement Protective Claim being filed pending assumption or rejection of executory contract. All rights reserved. See attached cure objection incorporated herein by reference.							
9.	Is all or part of the claim secured?	No Yes. The claim is secured by a lien on property. Nature of property: Real estate: If the claim is secured by the debtor's principal residence, file a Mortgage Proof of Claim Attachment (Official Form 410-A) with this Proof of Claim. Motor vehicle Other. Describe: Basis for perfection: Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.) Value of property: Amount of the claim that is secured: Amount of the claim that is unsecured: \$							
10	. Is this claim based on a lease?	X No Yes. Amount necessary to cure any default as of the date of the petition. \$							
11	. Is this claim subject to a right of setoff?	▼ No Yes . Identify the property:							

Case 24-80040-sgj11 Claim 4-1 Filed 07/22/24 Desc Main Document Page 3 of 13

12. Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?	X	No No Otron						Amo	ount entitled to priority
A claim may be partly priority and partly		☐ Domes	tic support obl .C. § 507(a)(1	igations (inclu		and child su	pport) under	\$	
nonpriority. For example, in some categories, the law limits the amount entitled to priority.			3,350* of dep s for personal					r	
Simulation priority.		days b	, salaries, or o efore the bank ver is earlier.	cruptcy petition	n is filed or t			s, \$	
		■ Taxes	or penalties ov	ved to governr	mental units.	11 U.S.C. §	507(a)(8).	\$	
		Contrib	outions to an e	mployee bene	efit plan. 11	U.S.C. § 507	(a)(5).	\$	
		Other.	Specify subse	ection of 11 U.	S.C. § 507(a	a)() that ap	plies.	\$	
		* Amounts a	are subject to adj	justment on 4/01	/25 and every	3 years after the	nat for cases be	gun on or af	ter the date of adjustment.
13. Is all or part of the claim entitled to administrative priority pursuant to 11 U.S.C. § 503(b)(9)?		days before		ommencemer	nt of the abo	ve case, in v	vhich the goo	ds have be	the debtor within 20 een sold to the Debtor in claim.
Part 3: Sign Below									
The person completing this proof of claim must sign and date it. FRBP 9011(b). If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is. A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.	I inder the am I have I declar Execute	am the truston am a guarar restand that a sount of the control examined the re under period and the control examined the don date. Michael L. gnature The name of the control examined the name of the control examined t	tor. tor's attorney of the debt of the control of the debt of the control of the	or, or their aut dorser, or othe ignature on thi itor gave the d in this <i>Proof of</i> that the foreg	ting and signature the company in the company in the recompany in the recompany in the recompany in the company	Bankruptcy F laim serves a for any paym nave reasona and correct. gning this cla ame	Rule 3005. as an acknowlents received able belief that the saim:	toward the the inform	that when calculating e debt. ation is true and correct.
			Denver, CC) 80231 USA	4	State	7IP (Code	Country
	Contact	phone	720-931-11	88		Julio	Email		huster@polsinelli.com

Trinitee G. Green (SBN 24081320) P. Kyle Cheves (SBN 24126723) Polsinelli PC 2950 N. Harwood, Suite 2100 Dallas, Texas 75201

Telephone: (214) 397-0030 Facsimile: (214) 397-0033 tggreen@polsinelli.com kcheves@polsinelli.com Michael Shuster (*Pro Hac Vice* forthcoming) Polsinelli PC 1401 Lawrence Street, Suite 2300 Denver, CO 80231 Telephone: (720) 931-1188 mschuster@polsinelli.com

COUNSEL TO FUJIFILM DIOSYNTH BIOTECHNOLOGIES USA, INC.

IN THE UNITED STATES BANKRUPTCY COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION

In re:	§	Chapter 11
	§	
EIGER BIOPHARMACEUTICALS,	§	Case No. 24-80040-sgj
INC., ¹	§	
	§	
Debtor.	§	

FUJIFILM DIOSYNTH BIOTECHNOLOGIES, U.S.A., INC.'S OBJECTION AND RESERVATION OF RIGHTS REGARDING DEBTORS' NOTICE OF CURE AMOUNTS AND POTENTIAL ASSUMPTION AND ASSIGNMENT OF EXECUTORY CONTRACTS AND UNEXPIRED LEASES IN CONNECTION WITH THE REMAINING ASSET SALE TRANSACTION(S)

Fujifilm Diosynth Biotechnologies, U.S.A., Inc. ("Fujifilm"), by and through their undersigned counsel, files this Objection and Reservation of Rights with respect to the Debtors' Notice of Cure Amounts and Potential Assumption and Assignment of Executory Contracts and Unexpired Leases in Connection with the Remaining Asset Sale Transaction(s) [Dkt. No. 313], ("Remaining Sale Cure Notice"), and states as follows:

¹ The Debtors in these chapter 11 cases, together with the last four digits of each Debtor's federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors' service address is 2155 Park Boulevard, Palo Alto, California 94306.



BACKGROUND

- 1. Eiger Biopharmaceuticals, Inc. and the related debtors (the "**Debtors**") filed their voluntary petitions for relief under chapter 11 of title 11 of the United States Code, 11 U.S.C. § 101, et seq. (the "**Bankruptcy Code**") on April 1, 2024 (the "**Petition Date**").
- 2. Fujifilm is party to a Master Bioprocessing Services Agreement with Debtor Eiger Biopharmaceuticals, Inc. dated September 22, 2016 ("Master Agreement").
- 3. On April 5, 2024, the Court entered its Order (I)(A) Approving the Bid Procedures; (B) Authorizing the Debtors to Select Sentynl Therapeutics, Inc. as the Zokinvy Stalking Horse Purchaser & Approving Bid Protections; (C) Approving the Bid Protections Relating to the Remaining Assets Stalking Horse Purchaser(s), if Any; (D) Establishing Bid Deadlines, Auction(s), and Sale Hearing(s); (E) Approving the Form and Manner of Sale Notice; (F) Approving Assignment and Assumption Procedures; (G) Approving the Form and Manner of Potential Assumption and Assignment Notice; (II)(A) Authorizing the Sale of the Assets Free and Clear; and (B) Approving the Assumption and Assignment of Designated Contracts; and (III) Granting Related Relief [Dkt. No. 94] ("Bid Procedures Order").
- 4. On June 4, 2024, pursuant to the Bid Procedures Order, the Debtors filed the Remaining Sale Cure Notice identifying certain contracts and leases the Debtors intend to potentially assume and assign in connection with potential remaining asset transaction(s).
- 5. The Remaining Sale Cure Notice includes forty-four (44) "Contracts" between the Debtors and Fujifilm, itemized as Numbers 455 through 494 as Exhibit A to the Remaining Sale Cure Notice. All the Debtors' designations regarding Fujifilm show "Lambda" as the "Related Asset" with a proposed collective cure amount of \$25,000 ("**Proposed Cure Amount**"). None of

the entries on Exhibit A refer to the Master Agreement, but instead, describe specific "Scopes of Work" and "Change Orders," which are defined terms under the Master Agreement.

OBJECTION

I. The Proposed Cure Amount is Incorrect

- 6. Fujifilm objects to the Remaining Sale Cure Notice based upon its failure to comply with 11 U.S.C. § 365, which governs the assumption and assignment of unexpired leases and executory contracts.
- 7. Pursuant to section 365 of the Bankruptcy Code, the Debtors must cure, or provide adequate assurance that they will promptly cure, all outstanding amounts owed under the Master Agreement before they can be assumed and certainly before they can be assigned.
- 8. Debtors' unpaid cure obligations to Fujifilm are set forth in **Exhibit A** attached hereto, which demonstrates a minimum necessary cure amount of \$202,280. Without limitation, the calculations shown on Exhibit A include Program Termination Fees and other fees charged under Section 2.1(e) of the Master Agreement.
- 9. As a condition to assumption and assignment of the Master Agreement, all unpaid prepetition and postpetition amounts due and owing to Fujifilm must be paid. The Debtors should not be relieved of liability for cure costs unless and until they are paid by the Buyer.

II. Fujifilm is Entitled to Adequate Assurance of Future Performance

- 10. Section 23 of the Master Agreement requires the prior consent of Fujifilm to any assignment thereof, and any buyer must be a party with whom Fujifilm is willing and able to do business.
- 11. Fujifilm must receive, and is entitled to, sufficient information from a buyer that would allow Fujifilm to determine whether such buyer qualifies as an assignee under the Master

Agreement, and Fujifilm to object to approval of any sale to an entity that has not provided such information or to an entity that has provided the information but who falls short on its ability to provide adequate assurance of future performance.

III. The Entire Master Agreement Must be Assumed and Assigned

- 12. Although the Debtors have described its contract with Fujifilm as "Scopes of Work" and "Change Orders," the executory contract between the parties is the Master Agreement.
- 13. Accordingly, the Master Agreement must be assumed and assigned in whole, and the Debtors cannot choose to assume and assign individual "Scopes of Work" under the Master Agreement, while rejecting others. *See, e.g., Stewart Title Guar. Co. v. Old Republic Nat. Title Ins. Co.*, 83 F.3d 735, 741 (5th Cir. 1996) ("It is well established that as a general proposition an executory contract must be assumed or rejected in its entirety.")

RESERVATION OF RIGHTS

- 14. Fujifilm reserves all of its rights under the Master Agreement, including the right to receipt of a proper cure amount pursuant to 11 U.S.C. § 365. Fujifilm reserves all of its rights with respect to the Master Agreement to any purported assumption and assignment or any other transfer of any portion of the Master Agreement in connection with any proposed sale.
- 15. Fujifilm reserves all of its rights with respect to payment owed for both prepetition and postpetition goods and services, and with respect to any executory contracts with the Debtors, including with respect to any cure or damages for rejection thereof and/or to enforce its rights and remedies under applicable law, or as otherwise authorized by the Court.
- 16. Fujifilm reserves its right to amend or supplement the foregoing objections, to join in other objections filed and to further revise and/or amend the foregoing, or to enforce other

CaSas24239800450gis1gi11ClaDiooc4327 Fffided00062222244 DienteManin060/062/204en1:21:20age13esfc13 Main Document Page 5 of 6

rights and remedies under applicable law, or as otherwise authorized by the Court.

Dated: June 12, 2024. Respectfully submitted,

POLSINELLI PC

By: /s/ Trinitee G. Green

Trinitee G. Green, Texas Bar No. 24081320 P. Kyle Cheves, Texas Bar No. 24126723 2950 N. Harwood, Suite 2100

Dallas, TX 75201 Phone: 214.397.0030

Email: tggreen@polsinelli.com kcheves@polsinelli.com

By: /s/ Michael L. Schuster

Michael L. Schuster, *pro hac vice* forthcoming 1401 Lawrence Street, Suite 2300

Denver, CO 80202 Phone: (720) 931-1188

Email: mschuster@polsinelli.com

COUNSEL FOR FUJIFILM DIOSYNTH BIOTECHNOLOGIES USA, INC.

CERTIFICATE OF SERVICE

The undersigned certifies that on June 12, 2024, she caused CM/ECF participants registered to receive ECF service in the above-captioned cases to be served with the foregoing Objection. Additionally, the undersigned counsel certifies that she caused her office to email a copy of the Objection as follows:

Proposed Debtors' Counsel

Sidley Austin LLP

Thomas R. Califano (tom.califano@sidley.com)

William E. Curtin (wcurtin@sidley.com)

Anne G. Wallice (anne.wallice@sidley.com)

Office of the United States Trustee

1100 Commerce Street, Room 976

Dallas, TX 75242

Attn: Elizabeth A. Young (elizabeth.a.young@usdoj.gov)

Counsel to Innovatus

Bradley Arant Boult Cummings LLP Roger Jones (rjones@bradley.com) Jay Bender (jbender@bradley.com)

Official Committee of Unsecured Creditors²

Rob Howey (rob.howey@connorgp.com)
Brian Chaiken (bchaiken@biorasi.com)

By: <u>/s/ Trinitee G. Green</u> Trinitee G. Green

² The Official Committee of Unsecured Creditors was first appointed on June 10, 2024 (Docket No. 322), and has not yet filed an application to appear through and retain counsel.

EXHIBIT A

Causse 2244-83000410-sagj/1111. Claim 82/71-1 Fiftiel d0 0/6/12/2124 Dientekkenin 6/06/06/02/024eint: 21:12-0 ge Diensof Exhibit A 118 age 2 of 4

EXHIBIT A TO CURE OBJECTION OF FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.

sow / co	Stage #	Stage Description	Invoice No	Amount Unpaid Invoices Due (\$)	Amount Contracted Due Not Invoiced (\$)	Amount Owed for Services Performed Not Contracted due to Cancellation (\$)	Amount Owed for Cancellation	Amount remaining if work continues (For Information Purposes) (\$)
SOW 5	Stage 1	DS Stability Protocol DS-1 Lot 14PY5040002 Stability Closure	2080014598	10,000	-	-	-	-
SOW 6	Stage 1	DS Stability STAB-PY117DS-3 Lot PY5040002 Protocol Revision Completed due to Cancellation Unsigned SOW 6 CO 1			-	10,000	-	-
SOW 6	Stage 1	DS Stability STAB-PY117DS-3 Lot PY5040002 36M 50% Cancellation Unsigned SOW 6 CO 1			-	-	19,625	-
SOW 14	Stage 1	DP Stability Protocol STAB-PY117DP- 2 Lot 0002 Stability Closure	2080015228	5,000	-	-	-	-
SOW 14		DP Stability Protocol STAB-PY117DP- 2 Lot 0002 Protocol Revision Completed due to Cancellation Unsigned SOW 14 CO 2				10,000	-	-
SOW 14 CO 1	Stage 1b	DP Stability Protocol STAB-PY117DP- 4 Lot 00004 Stability Closure	2080014171	10,000	-	-	-	-
SOW 14 CO 1	Stage 1a	DP Stability STAB-PY117DP-3 Lot 00003 Customer had originally requested at the notice of Cancellation Dec 2023 to continue this Study			-	-	-	95,000

Casse 2241-88000400-sagjj1111 Chaim 824-71-1 Fifteld d0 0/62/22/24 Dientelkhadin 0 6/01/21/24 echt: 21:12/9 ech2 sof Exhibit A 118 age 3 of 4

sow / co	Stage #	Stage Description	Invoice No	Amount Unpaid Invoices Due (\$)	Amount Contracted Due Not Invoiced (\$)	Amount Owed for Services Performed Not Contracted due to Cancellation (\$)	Amount Owed for Cancellation	Amount remaining if work continues (For Information Purposes) (\$)
SOW 14 CO 1	Stage 1b	DP Stability Protocol STAB-PY117DP- 4 Lot 00004 Protocol Revision Completed due to Cancellation Unsigned SOW 14 CO 2			-	10,000	-	-
SOW 14 CO 1	Stage 1b	DP Stability Protocol STAB-PY117DP- 4 Lot 00004 24M 50% Cancellation				_	15,000	_
30W 14 CO 1	Stage ID				_		13,000	-
SOW 14 CO 1	Stage 1d	Unsigned SOW 14 CO 2 DP-6 (Lot TBD) Credit Note to be Issued Back under Unsigned SOW 14 CO 2. As Invoice Paid but No Service Provided	PAID		(10,000)	-	-	-
SOW 14 CO 1	Stage 1e	DP-7 (Lot TBD) Credit Note to be Issued Back under Unsigned SOW 14 CO 2. As Invoice Paid but No Service Provided	PAID		(10,000)	-	-	-
SOW 14 CO 1	Stage 1f	DP-8 (Lot TBD) Credit Note to be Issued Back under Unsigned SOW 14 CO 2. As Invoice Paid but No Service Provided	PAID		(10,000)	-	-	-
SOW 15	Stage 3	DS Stability STAB-PY117DS-4 Lot 14PY5040003 Protocol Revision Completed due to Cancellation			-	10,000	-	-
SOW 15	Stage 4	Unsigned SOW 15 CO 1 DS Stability STAB-PY117DS-5 Lot 14PY5040004 Protocol Revision Completed due to Cancellation			-	10,000	-	-
SOW 15	Stage 5	Unsigned SOW 15 CO 1 DS Stability STAB-PY117DS-6 Lot PY5040003 Protocol Revision Completed due to Cancellation			-	10,000	-	-
SOW 15	Stage 5	Unsigned SOW 15 CO 1 DS Stability STAB-PY117DS-6 Lot PY5040003 18M 50% Cancellation Unsigned SOW 15 CO 1			-	-	21,000	-

Casse 224-830040-sgjj111 Claim 827-1 FHide 0006/22/24 Die stekted 106/06/24 eht: 21:20 ge Die sof Exhibit A 18 age 4 of 4

sow / co	Stage #	Stage Description	Invoice No	Amount Unpaid Invoices Due (\$)	Amount Contracted Due Not Invoiced (\$)	Amount Owed for Services Performed Not Contracted due to Cancellation (\$)	Amount Owed for Cancellation	Amount remaining if work continues (For Information Purposes) (\$)
SOW 15	Stage 6	DS Stability STAB-PY117DS-7 Lot PY5040004 Protocol Revision Completed due to Cancellation			-	10,000	-	-
SOW 15	Stage 6	Unsigned SOW 15 CO 1 DS Stability STAB-PY117DS-7 Lot PY5040004 9M 50% Cancellation Unsigned SOW 15 CO 1			-	-	24,650	-
		Consumables Passthrough Invoiced May 2024	2080016567	8,299	-	-		-
		Consumables Passthrough Invoiced Apr 2024	2080015775	4,848	-	-		-
		Consumables Passthrough Invoiced Apr 2024	2080015774	35,060	-	-		-
		Consumables Passthrough Invoiced Apr 2024	2080015770	2,922	-	-		-
		Consumables Passthrough To Be Invoiced				5,876		-
			TOTALS	: 76,129	(30,000)	75,876	80,275	95,000

GRAND TOTAL: 202,280